270 likes | 295 Views
Explore mechanisms of immunity, genetics, antigenic drift, vaccination, challenges, and guidelines for combating H1N1 influenza virus.
E N D
Immunity and vaccination to InfluenzaH1N1 – swine flu Mohammad S. KhalifehAssistant Professor, ImmunobiologyDepartment of Veterinary Basic Medical Science Department of Molecular Biology and Genetic Engineering Jordan University of Science and TechnologyTechnical consultantJordan biological Diagnostics Jordan Bio-industrial Center (JOVAC)
Influenza Genes • Influenza A viruses have 8 gene segments that encode 10 polypeptides • Segment 1 (2,341 nt): PB2 (RNA transcriptase) • Segment 2 (2,341 nt): PB1 (RNA transcriptase) • Segment 3 (2,233 nt): PA (RNA transcriptase) • Segment 4 (1,778 nt): HA (hemagglutinin) - 16 known subtypes • Segment 5 (1,565 nt): NP (nucleoprotein) • Segment 6 (1,413 nt): NA (neuraminidase) - 9 known subtypes • Segment 7 (1,027 nt): M1, M2 (matrix proteins) • Segment 8 (890 nt): NS1, NS2 (inhibits mRNA splicing and IFN response; nuclear export signal for viral RNPs)
Immunity to Influenza Virus Neutralization Y Y Y Antibody-mediated Opsonization Y Y Y Y Y HA Heterotypic Abs react with proteins of influenza Virus rather than HA and NA
What’s the Problem?!!! Immunopathogenesis and genetics
Type “A” Influenza Viruses Identified by 2 Surface Protein Structures Combinations “H” - Hemagglutinin (1 – 16) Entry into Cell “N” - Neuraminidase ( 1- 9) Exit from Cell 144 Possible combinations
Antigenic Drift “Do I know you? You look vaguely familiar!” Mutation H1N1 H1N1 • Imperfect “manufacturing” of virus • Small changes in H and N • Partial immunity in population • Incomplete protection; still get sick • Need new flu vaccine every year H1N1 This One I Know….. But Yearly epidemics occur H1N1
Antigenic Shift Oh my god…I don’t know you at all !!! This is all what I am seeing H1N1 H1N1 H1N1 H1N1 H1N1 Drives the occurrence of a pandemic Black is my favorite I am Color blind H1N1
Will a current flu vaccine protect me from Swine Flu? Answer: No Vaccines containing the 2008–09 trivalent vaccine virus strains include: • A/Brisbane/59/2007 (H1N1), • A/Brisbane/10/2007 (H3N2), and • B/Florida/4/2006 • All 3 vaccine virus strains were changed for the 2008-2009 season 2007-2008 Vaccine Strains: A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 viruses
Influenza Vaccines • Inactivated (TIV) • intramuscular • trivalent • contains egg protein • Live attenuated vaccine (LAIV) • intranasal • trivalent • contains egg protein
Inactivated Influenza Vaccine Efficacy • Duration of immunity for inactivated influenza vaccine is considered to be 1 year or less • The vaccine is actually effective two weeks after the shot is given. • 70%-90% effective among healthy persons <65 years of age • 30%-40% effective among frail elderly persons • 50%-60% effective in preventing hospitalization • 80% effective in preventing death
A pandemic soon…..Will A Vaccine Be Easy to Produce? • There will be little or no vaccine until 6 - 9 months after the outbreak begins • Production process is slow • 3-6 months until first doses are available • Longer until enough to cover all high-risk groups and general population • For seasonal influenza, viruses are grown in chicken eggs for 7 days to produce high-enough titers for vaccines • Avian influenza viruses kills eggs in 4.5 days • An insufficient titer is generated for vaccines • The world’s annual vaccine capacity is 300 million doses
Challenges • Vaccine Supply (annual uncertainty) • Recommendation vs. prioritization of high-risk groups • Vaccine Distribution (pre-booking) • Vaccine delivery • Vaccine Funding and over-reliance on public health
Live Attenuated Influenza Vaccine (LAIV) • Approved only for healthy persons 2 years through 49 years of age who are not pregnant • healthcare personnel • persons in close contact with high-risk groups • persons who want to reduce their risk of influenza MMWR 2008;57 (RR-7)
Influenza Vaccination • Influenza activity can occur as early as October • Continue to vaccinate throughout influenza season (December-March) • Pregnancy and Influenza Vaccine MMWR 2008;57 (RR-7)
“It would be better to have an immunization program without an epidemic than an epidemic without an immunization program.” (CDC, 1976)
USA guidelines for vaccine priority groups? Tier 1 A Vaccine Producers direct care medical workers B Persons > 65 with compromising conditions C Pregnant women; Household contacts of compromised persons D Public health emergency responders and key public officials. Tier 2 A Healthy 65 and older and children B Emergency response, essential services Tier 3 Key government and society leaders Tier 4 Healthy Persons
The only thing more difficult than planning would be explaining why you did not do it! -- Marja Esveld Healthcare Inspectorate, The Netherlands
WHO Phases of a Pandemic Current level
Lab Testing • Preferred specimen: nasopharyngeal/nasal swab, wash, aspirate • Rapid influenza tests • Results within 30 minutes • May determine type (A vs. B) • High false negative results (30%) • Viral culture • Results in 3-10 days • Determine specific subtype or strain • reference standard of diagnosis • Not necessary to test all patients • May not affect clinical decision-making • Expensive • Labor intensive • Cohort hospitalized patients • Outbreaks